Low-Dose, Single-Agent Temsirolimus for Relapsed Mantle Cell Lymphoma Ansell, Stephen M. , Inwards, David J. , Rowland, Kendrith M. ... - - Cancer - 2008 Manuscript - Primary - Primary - Lymphoma - N0186
Temsirolimus and Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma: a multi-center Phase 2 Study Ansell, Stephen M. , Tang, Hui , Kurtin, Paul J. ... - - Lancet Oncol - 2011 Manuscript - Primary - Primary - Lymphoma - N038H
Long-term Results of the Treatment of Patients With Mantle Cell Lymphoma With Cladribine (2-CDA) Alone (95-80-53) or 2-CDA and Rituximab (N0189) in the North Central Cancer Treatment Group Inwards, David J. , Fishkin, Paul A. S. , Hillman, David W. ... - - Cancer - 2008 Manuscript - Secondary-not-in-original - Long-Term-Followup - Lymphoma - N0189 , NCCTG-95-80-53
Everolimus plus R-CHOP-21 is Safe and Highly Effective for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Phase I Trial NCCTG N1085 (Alliance) Johnston, Patrick B. , LaPlant, Betsy R. , McPhail, Ellen D. ... - ASH - Blood - 2015 Abstract - Primary - Primary - Lymphoma - N1085
The mTORC1 Inhibitor Everolimus Combined with R-CHOP-21 for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Safety and Efficacy Results of a Phase I and Feasibility Trial NCCTG 1085 (Alliance) Johnston, Patrick B. , LaPlant, Betsy , McPhail, Ellen ... - - Lancet Haematol - 2016 Manuscript - Primary - Primary - Lymphoma - N1085
Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials Maurer, Matthew J. , Ghesquières, Hervé , Link, Brian K. ... - - J. Clin. Oncol - 2018 Manuscript - Primary - Primary - Lymphoma - A151814
Elevated Serum Free Light Chains Are Associated With Event-Free and Overall Survival in Two Independent Cohorts of Patients With Diffuse Large B-Cell Lymphoma Maurer, Matthew J. , Micallef, Ivana N.M. , Cerhan, James R. ... - - J Clin Oncol - 2011 Manuscript - Secondary-not-in-original - Primary - Lymphoma - N0489
Bendamustine and rituximab and lenalidomide (BRR) in the treatment of relapsed and refractory low grade non-Hodgkin lymphoma (NHL): Final results of phase 1 study NCCTG N1088/Alliance Nowakowski, Grzegorz S. , LaPlant, Betsy , Macon, William R. ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Primary - Primary - Lymphoma - N1088
Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: A phase II trial in the North Central Cancer Treatment Group Witzig, Thomas E. , Geyer, Susan M. , Kurtin, Paul J. ... - - Leuk. Lymphoma - 2008 Manuscript - Primary - Primary - Lymphoma - N9981
